{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T15:45:57Z","timestamp":1792856757975,"version":"4.5.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Bristol Myers Squibb"}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Idiopathic pulmonary fibrosis is a fatal and progressive disease with limited treatment options.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>We sought to assess the efficacy and safety of CC-90001, an oral inhibitor of c-Jun N-terminal kinase 1, in patients with idiopathic pulmonary fibrosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In a Phase 2, randomized (1:1:1), double-blind, placebo-controlled study (ClinicalTrials.gov ID: NCT 03142191), patients received CC-90001 (200 or 400\u2009mg) or placebo once daily for 24\u2009weeks. Background antifibrotic treatment (pirfenidone) was allowed. The primary endpoint was change in the percentage of predicted FVC (ppFVC) from baseline to Week 24; secondary endpoints included safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements and Main Results<\/jats:title>\n                    <jats:p>In total, 112 patients received at least one dose of study drug. The study was terminated early because of a strategic decision made by the sponsor. Ninety-one patients (81%) completed the study. The least-squares mean changes from baseline in ppFVC at Week 24 were \u22123.1% (placebo), \u22122.1% (200\u2009mg), and \u22121.0% (400\u2009mg); the differences compared with placebo were 1.1% (200\u2009mg; 95% confidence interval: \u22122.1, 4.3; P\u2009=\u20090.50) and 2.2% (400\u2009mg; 95% confidence interval: \u22121.1, 5.4; P\u2009=\u20090.19). Adverse event frequency was similar in patients in the combined CC-90001 arms versus placebo. The most common adverse events were nausea, diarrhea, and vomiting, which were more frequent in patients in CC-90001 arms versus placebo. Fewer patients in the CC-90001 arms than in the placebo arm experienced cough and dyspnea.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Treatment with CC-90001 over 24\u2009weeks led to numerical improvements in ppFVC in patients with idiopathic pulmonary fibrosis compared with placebo. CC-90001 was generally well tolerated, which was consistent with previous studies.<\/jats:p>\n                    <jats:p>Clinical trial registered with www.clinicaltrials.gov (NCT 03142191).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1164\/rccm.202310-1907oc","type":"journal-article","created":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T14:40:17Z","timestamp":1710427217000},"page":"435-443","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":27,"title":["Phase 2, Double-Blind, Placebo-controlled Trial of a c-Jun N-Terminal Kinase Inhibitor in Idiopathic Pulmonary Fibrosis"],"prefix":"10.1093","volume":"210","author":[{"given":"Waldo L. L. D.","family":"Mattos","sequence":"first","affiliation":[{"name":"Hospital Nossa Senhora da Concei\u00e7\u00e3o, Porto Alegre, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasreen","family":"Khalil","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa G.","family":"Spencer","sequence":"additional","affiliation":[{"name":"Aintree Chest Centre, Liverpool University Hospital NHS Foundation Trust, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7579-9767","authenticated-orcid":false,"given":"Francesco","family":"Bonella","sequence":"additional","affiliation":[{"name":"Center for Interstitial and Rare Lung Disease, Department of Pneumology, Ruhrlandklinik, University of Duisburg-Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney J.","family":"Folz","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Critical Care and Sleep Medicine, Houston Methodist Research Institute, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Douglass","family":"Rolf","sequence":"additional","affiliation":[{"name":"Kelowna Respiratory Clinic, Kelowna, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nesrin","family":"Mogulkoc","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Ege University Hospital, Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa H.","family":"Lancaster","sequence":"additional","affiliation":[{"name":"Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Gisli","family":"Jenkins","sequence":"additional","affiliation":[{"name":"Imperial Biomedical Research Center and"},{"name":"Royal Brompton and Harefield Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Lynch","sequence":"additional","affiliation":[{"name":"Department of Radiology, National Jewish Health, Denver, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul W.","family":"Noble","sequence":"additional","affiliation":[{"name":"Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7192-9149","authenticated-orcid":false,"given":"Toby M.","family":"Maher","sequence":"additional","affiliation":[{"name":"Interstitial Lung Disease Unit, National Heart and Lung Institute, Imperial College London, London, United Kingdom"},{"name":"Keck School of Medicine, University of Southern California, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5591-0955","authenticated-orcid":false,"given":"Vincent","family":"Cottin","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Louis Pradel Hospital, Lyon, France"},{"name":"University Claude Bernard Lyon 1, UMR 754, INRAE, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Senger","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, New Jersey; and"},{"name":"Cytel Inc., Waltham, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald S.","family":"Horan","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, New Jersey; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Greenberg","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, New Jersey; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoran","family":"Popmihajlov","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, New Jersey; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,15]]},"reference":[{"key":"2026022020472405400_bib1","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","article-title":"An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management","volume":"183","author":"Raghu","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"2026022020472405400_bib2","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N Engl J Med"},{"key":"2026022020472405400_bib3","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N Engl J Med"},{"key":"2026022020472405400_bib4","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/j.chest.2021.06.049","article-title":"Impact of antifibrotic therapy on mortality and acute exacerbation in idiopathic pulmonary fibrosis: a systematic review and meta-analysis","volume":"160","author":"Petnak","year":"2021","journal-title":"Chest"},{"key":"2026022020472405400_bib5","first-page":"1724","article-title":"Antifibrotic therapies reduce mortality and hospitalization among Medicare beneficiaries with idiopathic pulmonary fibrosis","volume":"27","author":"Mooney","year":"2021","journal-title":"J Manag Care Spec Pharm"},{"key":"2026022020472405400_bib6","doi-asserted-by":"crossref","first-page":"00084-2018","DOI":"10.1183\/23120541.00084-2018","article-title":"Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study","volume":"4","author":"Cottin","year":"2018","journal-title":"ERJ Open Res"},{"key":"2026022020472405400_bib7","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s12931-022-01974-2","article-title":"Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial","volume":"23","author":"Cottin","year":"2022","journal-title":"Respir Res"},{"key":"2026022020472405400_bib8","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1183\/09031936.06.00012106","article-title":"c-Jun N-terminal kinase-dependent mechanisms in respiratory disease","volume":"28","author":"Bennett","year":"2006","journal-title":"Eur Respir J"},{"key":"2026022020472405400_bib9","doi-asserted-by":"crossref","first-page":"e0226904","DOI":"10.1371\/journal.pone.0226904","article-title":"Airway epithelial specific deletion of Jun-N-terminal kinase 1 attenuates pulmonary fibrosis in two independent mouse models","volume":"15","author":"van der Velden","year":"2020","journal-title":"PLoS One"},{"key":"2026022020472405400_bib10","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/j.bmcl.2011.12.027","article-title":"Discovery of CC-930, an orally active anti-fibrotic JNK inhibitor","volume":"22","author":"Plantevin Krenitsky","year":"2012","journal-title":"Bioorg Med Chem Lett"},{"key":"2026022020472405400_bib11","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s40169-016-0117-2","article-title":"JNK inhibition reduces lung remodeling and pulmonary fibrotic systemic markers","volume":"5","author":"van der Velden","year":"2016","journal-title":"Clin Transl Med"},{"key":"2026022020472405400_bib12","doi-asserted-by":"crossref","first-page":"18193","DOI":"10.1021\/acs.jmedchem.1c01716","article-title":"Discovery of the c-Jun N-terminal kinase inhibitor CC-90001","volume":"64","author":"Nagy","year":"2021","journal-title":"J Med Chem"},{"key":"2026022020472405400_bib13","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1002\/cpdd.1178","article-title":"Safety, pharmacokinetics, and pharmacodynamics of CC-90001 (BMS-986360), a c-Jun N-terminal kinase inhibitor, in phase 1 studies in healthy participants","volume":"11","author":"Ye","year":"2022","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2026022020472405400_bib14","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/cpdd.1294","article-title":"Safety, pharmacokinetics, and antifibrotic activity of CC-90001 (BMS-986360), a c-Jun N-terminal kinase inhibitor, in pulmonary fibrosis","volume":"12","author":"Horan","year":"2023","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2026022020472405400_bib15","doi-asserted-by":"crossref","first-page":"e001060","DOI":"10.1136\/bmjresp-2021-001060","article-title":"CC-90001, a c-Jun N-terminal kinase (JNK) inhibitor, in patients with pulmonary fibrosis: design of a phase 2, randomised, placebo-controlled trial","volume":"9","author":"Popmihajlov","year":"2022","journal-title":"BMJ Open Respir Res"},{"key":"2026022020472405400_bib16","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S2213-2600(17)30433-2","article-title":"Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society white paper","volume":"6","author":"Lynch","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2026022020472405400_bib17","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.2214\/AJR.17.18947","article-title":"CT-pathologic correlation of major types of pulmonary fibrosis: insights for revisions to current guidelines","volume":"210","author":"Chung","year":"2018","journal-title":"AJR Am J Roentgenol"},{"key":"2026022020472405400_bib18","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1080\/00498254.2022.2027553","article-title":"Assessment of drug-drug interactions of CC-90001, a potent and selective inhibitor of c-Jun N-terminal kinase","volume":"51","author":"Tong","year":"2021","journal-title":"Xenobiotica"},{"key":"2026022020472405400_bib19","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12916-016-0558-x","article-title":"Treatment of idiopathic pulmonary fibrosis: a network meta-analysis","volume":"14","author":"Rochwerg","year":"2016","journal-title":"BMC Med"},{"key":"2026022020472405400_bib20","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1055\/a-1579-7618","article-title":"A new tool to assess quality of life in patients with idiopathic pulmonary fibrosis or non-specific interstitial pneumonia","volume":"76","author":"Kirsten","year":"2022","journal-title":"Pneumologie"},{"key":"2026022020472405400_bib21","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12931-019-1118-7","article-title":"Biomarkers of collagen synthesis predict progression in the PROFILE idiopathic pulmonary fibrosis cohort","volume":"20","author":"Organ","year":"2019","journal-title":"Respir Res"},{"key":"2026022020472405400_bib22","first-page":"PA2254","article-title":"Effect of nintedanib on blood biomarkers in patients with IPF in the INMARK trial","volume":"54","author":"Jenkins","year":"2019","journal-title":"Eur Respir J"},{"key":"2026022020472405400_bib23","first-page":"A7301","article-title":"Omipalasib modulates extracellular matrix turnover in IPF patients: exploratory biomarker analysis from a phase I proof of mechanism study","volume":"199","author":"Nanthakumar","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"2026022020472405400_bib24","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/apt.12820","article-title":"Review article: the efficacy of biomarkers in chronic fibroproliferative diseases\u2014early diagnosis and prognosis, with liver fibrosis as an exemplar","volume":"40","author":"Karsdal","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"2026022020472405400_bib25","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/1471-2466-14-120","article-title":"Lung fibrotic tenascin-C upregulation is associated with other extracellular matrix proteins and induced by TGF\u03b21","volume":"14","author":"Estany","year":"2014","journal-title":"BMC Pulm Med"},{"key":"2026022020472405400_bib26","doi-asserted-by":"crossref","first-page":"L785","DOI":"10.1152\/ajplung.00385.2009","article-title":"Tenascin-C deficiency attenuates TGF-\u00df-mediated fibrosis following murine lung injury","volume":"299","author":"Carey","year":"2010","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"2026022020472405400_bib27","doi-asserted-by":"crossref","first-page":"11703","DOI":"10.1038\/ncomms11703","article-title":"Tenascin-C drives persistence of organ fibrosis","volume":"7","author":"Bhattacharyya","year":"2016","journal-title":"Nat Commun"},{"key":"2026022020472405400_bib28","doi-asserted-by":"crossref","first-page":"e862","DOI":"10.1016\/S2589-7500(22)00173-X","article-title":"Forced vital capacity trajectories in patients with idiopathic pulmonary fibrosis: a secondary analysis of a multicentre, prospective, observational cohort","volume":"4","author":"Fainberg","year":"2022","journal-title":"Lancet Digit Health"},{"key":"2026022020472405400_bib29","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1056\/NEJMoa2201737","article-title":"Trial of a preferential phosphodiesterase 4b inhibitor for idiopathic pulmonary fibrosis","volume":"386","author":"Richeldi","year":"2022","journal-title":"N Engl J Med"},{"key":"2026022020472405400_bib30","author":"Keenan","year":"2023"},{"key":"2026022020472405400_bib31","first-page":"782","article-title":"INTEGRIS-IPF: a 12-week, phase 2a study evaluating the safety, tolerability and pharmacokinetics of PLN-74809 in participants with IPF","volume":"56","author":"Lefebvre","year":"2020","journal-title":"Eur Respir J"},{"key":"2026022020472405400_bib32","doi-asserted-by":"crossref","first-page":"799912","DOI":"10.3389\/fmed.2022.799912","article-title":"The burden of progressive-fibrosing interstitial lung diseases","volume":"9","author":"Cottin","year":"2022","journal-title":"Front Med (Lausanne)"}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/210\/4\/435\/66997965\/ajrccm_210_4_435.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/210\/4\/435\/66997965\/ajrccm_210_4_435.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T01:47:32Z","timestamp":1771638452000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/210\/4\/435\/8491456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":32,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,8,15]]},"published-print":{"date-parts":[[2024,8,15]]}},"URL":"https:\/\/doi.org\/10.1164\/rccm.202310-1907oc","relation":{},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,8]]},"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"2023-11-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}